 Raymond James lowered the price target on AngioDynamics Inc NASDAQ: ANGO to 27 from 32 based on a 3.0x group multiple applied to the C23 revenue estimate. At 2.2x EVsales, Raymond James believes ANGO is undervalued given its growth profile and expects the multiple to expand with continued. 